May 20, 2014 — Siemens Healthcare announced the U.S. Food and Drug Administration (FDA) has cleared the 16- and 32-slice iterations of its Somatom Perspective computed tomography (CT) system.

GE Healthcare Partners With Tesla Engineering to Produce Ultra High-Field 7T MRI Systems

May 20, 2014 — GE Healthcare and Tesla Engineering Ltd. are collaborating to produce 7T human whole-body magnetic resonance imaging (MRI) scanners. The companies made the announcement at the joint meeting of the International Society for Magnetic Resonance in Medicine (ISMRM) and the European Society for Magnetic Resonance in Medicine and Biology (ESMRMB) in Milan.

May 19, 2014 — GE Healthcare and CorTechs Labs announced the signing of a strategic joint-marketing agreement at the joint meeting of the International Society of Magnetic Resonance in Medicine (ISMRM) and the European Society of Magnetic Resonance in Medicine and Biology (ESMRMB), held in Milan. The companies will collaborate to co-market an MRI (magnetic resonance imaging) scanning solution combined with NeuroQuant, CorTechs Labs’ MRI post-processing application.

May 19, 2014 — NIA Magellan, a subsidiary of Magellan Health Services Inc., recently launched “RadZone Kids,” an easy-to-use community resource to assist parents and caregivers in preparing their children for various diagnostic imaging tests, including CT (computed tomography) scans, MRI (magnetic resonance imaging) scans and X-rays.

According to a study presented at the 2014 ARRS Annual Meeting in San Diego, misinformation and misunderstanding about the risks associated with ionizing radiation create heightened public concern and fear, and may result in avoidance of screening mammography that can detect early cancers.

 

May 19, 2014 — A Japanese multi-institutional study1 of 1,194 patients, has found that individuals with five to 10 tumors treated with Gamma Knife stereotactic radiosurgery alone (no whole brain radiation therapy) fared as well as a group with two to four tumors who received this radiosurgery-only treatment. 

Proton therapy is in the proverbial chicken or the egg scenario. Companies are pulling back on reimbursements to treat some cancers — notably prostate, breast and lung — because of the added expense and limited evidence to back it up.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now